Carl W. Baker

Ophthalmology

15 Lafayette Pl Ste C
Hilton Head Island, SC 29926

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 26 publications

Four-Year Visual Outcomes in the Protocol W Randomized Trial of Intravitreous Aflibercept for Prevention of Vision-Threatening Complications of Diabetic Retinopathy.

Four-Year Visual Outcomes in the Protocol W Randomized Trial of Intravitreous Aflibercept for Prevention of Vision-Threatening Complications of Diabetic Retinopathy.

Journal: JAMA

Published: February 07, 2023

A Step Forward in Understanding Treatment Approaches for Diabetic Macular Edema.

A Step Forward in Understanding Treatment Approaches for Diabetic Macular Edema.

Journal: JAMA ophthalmology

Published: November 10, 2022

Aflibercept Monotherapy or Bevacizumab First for Diabetic Macular Edema.

Aflibercept Monotherapy or Bevacizumab First for Diabetic Macular Edema.

Journal: The New England journal of medicine

Published: July 14, 2022

Comparison of Snellen Visual Acuity Measurements in Retinal Clinical Practice to Electronic ETDRS Protocol Visual Acuity Assessment.

Comparison of Snellen Visual Acuity Measurements in Retinal Clinical Practice to Electronic ETDRS Protocol Visual Acuity Assessment.

Journal: Ophthalmology

Published: July 14, 2022

A Randomized Trial of Photobiomodulation Therapy for Center-Involved Diabetic Macular Edema with Good Visual Acuity (Protocol AE).

A Randomized Trial of Photobiomodulation Therapy for Center-Involved Diabetic Macular Edema with Good Visual Acuity (Protocol AE).

Journal: Ophthalmology. Retina

Published: August 10, 2021

Effect of Initial Aflibercept, Laser, or Observation on Low-Contrast Visual Acuity in Eyes With Diabetic Macular Edema and Good Vision: Ancillary Study Within a Randomized Clinical Trial.

Effect of Initial Aflibercept, Laser, or Observation on Low-Contrast Visual Acuity in Eyes With Diabetic Macular Edema and Good Vision: Ancillary Study Within a Randomized Clinical Trial.

Journal: Translational vision science & technology

Published: May 18, 2021

Assessment of the DRCR Retina Network Approach to Management With Initial Observation for Eyes With Center-Involved Diabetic Macular Edema and Good Visual Acuity: A Secondary Analysis of a Randomized Clinical Trial.

Assessment of the DRCR Retina Network Approach to Management With Initial Observation for Eyes With Center-Involved Diabetic Macular Edema and Good Visual Acuity: A Secondary Analysis of a Randomized Clinical Trial.

Journal: JAMA ophthalmology

Published: February 21, 2020

Visual Field Changes Over 5 Years in Patients Treated With Panretinal Photocoagulation or Ranibizumab for Proliferative Diabetic Retinopathy.

Visual Field Changes Over 5 Years in Patients Treated With Panretinal Photocoagulation or Ranibizumab for Proliferative Diabetic Retinopathy.

Journal: JAMA ophthalmology

Published: January 31, 2020

Five-Year Outcomes after Initial Aflibercept, Bevacizumab, or Ranibizumab Treatment for Diabetic Macular Edema (Protocol T Extension Study).

Five-Year Outcomes after Initial Aflibercept, Bevacizumab, or Ranibizumab Treatment for Diabetic Macular Edema (Protocol T Extension Study).

Journal: Ophthalmology

Published: December 11, 2019

Effect of Initial Management With Aflibercept vs Laser Photocoagulation vs Observation on Vision Loss Among Patients With Diabetic Macular Edema Involving the Center of the Macula and Good Visual Acuity: A Randomized Clinical Trial.

Effect of Initial Management With Aflibercept vs Laser Photocoagulation vs Observation on Vision Loss Among Patients With Diabetic Macular Edema Involving the Center of the Macula and Good Visual Acuity: A Randomized Clinical Trial.

Journal: JAMA

Published: May 01, 2019

Re: Guymer et al.: Subthreshold nanosecond laser intervention in age-related macular degeneration: The LEAD Randomized Controlled Clinical Trial (Ophthalmology. 2019;126:829-838).

Re: Guymer et al.: Subthreshold nanosecond laser intervention in age-related macular degeneration: The LEAD Randomized Controlled Clinical Trial (Ophthalmology. 2019;126:829-838).

Journal: Ophthalmology

Published: April 29, 2019

Month 12 Outcomes After Treatment Change at Month 6 Among Poor Responders to Aflibercept or Bevacizumab in Eyes With Macular Edema Secondary to Central or Hemiretinal Vein Occlusion: A Secondary Analysis of the SCORE2 Study.

Month 12 Outcomes After Treatment Change at Month 6 Among Poor Responders to Aflibercept or Bevacizumab in Eyes With Macular Edema Secondary to Central or Hemiretinal Vein Occlusion: A Secondary Analysis of the SCORE2 Study.

Journal: JAMA ophthalmology

Published: December 28, 2018

Showing 1-12 of 26

Last Updated: 09/26/2026